UNSPSC 51294002: Eprobemide

This classification denotes an antidepressant agent and antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier URX5F7RDER. European Medicines Agency schedules Eprobemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06585MIG. Eprobemide generally arises in the molecular formula C14H19CLN2O2.

UNSPSC 51294002 Eprobemide is a Commodity code that in practice covers naloxone and drug deactivation systems procured by state and local health agencies to support community health and harm-reduction initiatives. State and local buyers use this code to acquire naloxone (an opioid overdose reversal medication) and safe drug deactivation or disposal systems, typically in multi-unit quantities for distribution through public health departments, community health facilities, and emergency response programs. Issuing bodies include county health departments and municipal health agencies focused on opioid crisis response and public health infrastructure.

Seminole County, Florida posted an IFB (Invitation for Bid) in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building. The bid required electronic submission through the county's e-Procurement Portal, with a response deadline of July 26, 2023 at 2:00 pm, and mandated E-Verify compliance, drug-free workplace certification, and specific insurance coverages including workers' compensation and commercial general liability. The contract structure included an initial two-year term with a one-year renewal option and a three-month probationary period; vendors bore all shipping and delivery costs as part of their bid price. The procurement carried potential FEMA funding and associated federal compliance obligations. Recent activity in this code is limited; the single available opportunity reflects county-level health procurement focused on opioid response and harm reduction.